Treatment Outcomes and Associated Factors of Intravenous Colistin for Nosocomial Infections in Pediatric Patients: A Retrospective Study in a University Hospital in Thailand

被引:1
作者
Khamlek, Sunisa [1 ,2 ]
Lucksiri, Aroonrut [3 ]
Sunkonkit, Kanokkarn [4 ]
Oberdorfer, Peninnah [5 ]
Sukwuttichai, Pattarapan [3 ,6 ]
机构
[1] Chiang Mai Univ, Fac Pharm, PhDs Degree Program Pharm, Chiang Mai, Thailand
[2] Univ Phayao, Sch Pharmaceut Sci, Dept Pharmaceut Care, Div Clin Pharm, Phayao, Thailand
[3] Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Care, 239 Suthep Rd, Chiang Mai 50200, Thailand
[4] Chiang Mai Univ, Fac Med, Dept Pediat, Div Pulm & Crit Care, Chiang Mai, Thailand
[5] Chiang Mai Univ, Fac Med, Dept Pediat, Div Infect Dis, Chiang Mai, Thailand
[6] Chiang Mai Univ, Fac Pharm, Pharmaceut Care Training Ctr, Dept Pharmaceut Care, Chiang Mai, Thailand
关键词
colistin; efficacy; safety; child; nosocomial infection; CRITICALLY-ILL CHILDREN; COMBINATION; EFFICACY; CRITERIA; RISK;
D O I
10.1097/INF.0000000000004450
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: This study aimed to investigate the efficacy and safety of intravenous colistin in pediatric patients with nosocomial Gram-negative bacteria infections and to determine factors associated with treatment outcomes. Methods: This retrospective study recruited patients <18 years of age receiving intravenous colistin between January 2014 and December 2018. Clinical data and treatment outcomes were reviewed, and factors associated with treatment outcomes were assessed. Results: This study included 178 patients with a median age of 3.4 years (range, 0.1-17.8). The mean +/- SD dose of colistin prescribed to patients without renal impairment was 5.1 +/- 0.6 mg/kg/day. The clinical response rate was 70.8% in patients receiving colistin for specific treatment. Infection-related mortality and crude mortality were 17.5% and 19.7%, respectively. The nephrotoxicity rate was 29.8%; approximately 70% of the episodes occurred between the 3rd and 7th day of treatment. The presence of at least 2 organ dysfunctions [adjusted hazard ratio (aHR): 7.17; 95% CI: 1.64-31.40], septic shock (aHR: 2.69; 95% CI: 1.36-5.32) and receiving chemotherapy/immunosuppressants (aHR: 2.68; 95% CI: 1.36-5.25) were observed to be associated with clinical failure. The factors observed to be associated with nephrotoxicity included hypoalbuminemia (aHR: 2.93; 95% CI: 1.26-6.78), receiving amphotericin B (aHR: 2.29; 95% CI: 1.16-4.52), vancomycin (aHR: 3.36; 95% CI: 1.50-7.56) and vasopressors (aHR: 2.57; 95% CI: 1.27-5.21). Conclusion: Colistin is generally effective in the treatment of nosocomial Gram-negative bacteria infections in pediatric patients. Close monitoring of renal function should be considered, especially in high-risk patients. Optimal dosage regimens for pediatric populations to promote more favorable clinical outcomes and minimize nephrotoxicity require further investigation.
引用
收藏
页码:1054 / 1060
页数:7
相关论文
共 39 条
[1]   Carbapenem-Resistant Gram-Negative Bacterial Infections in Children [J].
Aguilera-Alonso, David ;
Escosa-Garcia, Luis ;
Saavedra-Lozano, Jesus ;
Cercenado, Emilia ;
Baquero-Artigao, Fernando .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
[2]   Modified RIFLE criteria in critically ill children with acute kidney injury [J].
Akcan-Arikan, A. ;
Zappitelli, M. ;
Loftis, L. L. ;
Washburn, K. K. ;
Jefferson, L. S. ;
Goldstein, S. L. .
KIDNEY INTERNATIONAL, 2007, 71 (10) :1028-1035
[3]  
[Anonymous], 2013, Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals
[4]  
Second Informational Supplement
[5]   Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses [J].
Antachopoulos, Charalampos ;
Geladari, Anastasia ;
Landersdorfer, Cornelia B. ;
Volakli, Eleni ;
Ilia, Stavroula ;
Gikas, Evangelos ;
Gika, Helen ;
Sdougka, Maria ;
Nation, Roger L. ;
Roilides, Emmanuel .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (06)
[6]   The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literature [J].
Bal, Zumrut Sahbudak ;
Can, Fulya Kamit ;
Yazici, Pinar ;
Anil, Ayse Berna ;
Duyu, Muhterem ;
Ciftdogan, Dilek Yilmaz ;
Yilmaz, Ozkalay Nisel ;
Cilli, Feriha ;
Karapinar, Bulent .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (05) :370-375
[7]   Efficacy and safety of colistin loading dose: a meta-analysis [J].
Bellos, Ioannis ;
Pergialiotis, Vasilios ;
Frountzas, Maximos ;
Kontzoglou, Konstantinos ;
Daskalakis, Georgios ;
Perrea, Despina N. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (07) :1689-1698
[8]   Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections [J].
Cheng, Chien-Yu ;
Sheng, Wang-Huei ;
Wang, Jann-Tay ;
Chen, Yee-Chun ;
Chang, Shan-Chwen .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (03) :297-300
[9]   Appropriate use of colistin in neonates, infants and children: Interim guidance [J].
Chibabhai, Vindana ;
Bekker, Adrie ;
Black, Marianne ;
Demopoulos, Despina ;
Dramowski, Angela ;
Plessis, Nicolette M. du ;
Pillay-Fuentes, Veshni ;
Nana, Trusha ;
Rabie, Helena ;
Reubenson, Gary ;
Thomas, Reenu .
SOUTHERN AFRICAN JOURNAL OF INFECTIOUS DISEASES, 2023, 38 (01)
[10]   Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children [J].
Chiotos, Kathleen ;
Hayes, Molly ;
Gerber, Jeffrey S. ;
Tamma, Pranita D. .
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2020, 9 (01) :56-66